6.67
6.67 (0%)
As of Apr 25, 2025
Novavax Inc [NVAX]
Source:
Company Overview
Novavax, Inc. business is to tackling global health challenges through scientific innovation that seeks to maximize our deep scientific expertise in vaccines and our cutting-edge technology platform.
| Country | United States |
| Headquarters | gaithersburg, maryland |
| Phone Number | (240) 268-2000 |
| Industry | manufacturing |
| CEO | John C. Jacobs |
| Website | www.novavax.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $682.2 |
| Operating Profit | $-248.9 |
| Net Income | $-187.5 |
| Net Cash | $-38.5 |
Profit Ratios
| Gross Margin | $479.4 |
| Operating Margin | -36.5 |
| Profit as % of Revenues | -255.7% |
| Profit as % of Assets | -11.2% |
| Profit as % of Stockholder Equity | 30.1% |
Management Effectiveness
| Return on Equity | 30.1% |
| Return on Assets | -12% |
| Turnover Ratio | 40.6% |
| EBITA | $-248.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,560.4 |
| Total Liabilities | $2,184.3 |
| Operating Cash Flow | $-87.3 |
| Investing Cash Flow | $-204 |
| Financing Cash Flow | $260.6 |
